Oncology & Cancer

Idhifa approved for some with acute myeloid leukemia

(HealthDay)—Idhifa (enasidenib) has been approved by the U.S. Food and Drug Administration to treat adults with a specific genetic mutation that leads to relapsed or refractory acute myeloid leukemia (AML).

page 1 from 3